Advanced Biomed vs VirnetX
ADVB and VHC side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADVB and VHC compare
VirnetX is the larger company, worth 10 times as much as Advanced Biomed ($38.0M against $3.7M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADVB | VHC |
|---|---|---|
| Size and price | ||
| Market cap | $3.7M | $38.0M |
| Share price | $2.22 | $9.01 |
| Change, 1 year | −75.2% | −59.3% |
| Change, 5 years | – | −83.3% |
| Beta (5Y) | 1.32 | 1.27 |
| Employees | 12 | 13 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 0.4× | – |
| P/S | – | 333× |
| P/B | 0.3× (better) | 2.5× |
| Growth | ||
| Revenue growth (TTM) | – | 128% |
| Revenue growth, 5Y average | – | −77.8% |
| Profitability | ||
| Operating margin | – | −18078% |
| Net margin | – | −17374% |
| Return on equity | 84.8% (better) | −82.1% |
| Return on invested capital | – | −1044% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.33 (better) | 6.24 |
| Altman Z-score | 1.29 (better) | −13.58 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −6.8% | – |
| Shareholder yield | −6.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | – | 13.9% |
| Held by insiders | 0.00% | 17.5% |
| Insider net buying, 12 months | – | −$489K |
| Short interest, % of float | 0.68% | 3.9% |
Go deeper
- ADVB stock overview
- ADVB income statement
- ADVB valuation and score
- VHC stock overview
- VHC income statement
- VHC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.